the ageing population
The PK-Eye™ uses an in house simulated vitreous to mimic the clearance profiles of clinical therapeutic proteins and to mimic different patient populations. The simulated vitreous has been validated to estimate the human pharmacokinetic properties for proteins/peptides, small molecules and implants.
Clearance profiles of ranibizumab and bevacizumab in simulated vitreous in the PK-Eye™ mimics the human release kinetics
Awwad et al, J Pharm Sci. 2015; 104 (10):3330-3342; Awwad et al, Macromol Biosci. 2018; 18 (2):1700255